vida: extract from 2025-07-24-kff-medicare-advantage-2025-enrollment-update.md

- Source: inbox/archive/2025-07-24-kff-medicare-advantage-2025-enrollment-update.md
- Domain: health
- Extracted by: headless extraction cron (worker 2)

Pentagon-Agent: Vida <HEADLESS>

domains/health/CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md

@@ -34,6 +34,12 @@ The broader 2027 rate environment compounds the pressure into a three-pronged sq
 
 This is a proxy inertia story. Since [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]], the incumbents who built their MA economics around coding optimization will struggle to shift toward genuine quality competition. The plans that never relied on coding arbitrage (Devoted, Alignment, Kaiser) are better positioned.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-07-24-kff-medicare-advantage-2025-enrollment-update]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+
+The MA overpayment gap grew from $18B in 2015 to $84B in 2025 (4.7x growth) while enrollment only doubled, demonstrating that the per-enrollee overpayment increased substantially even as the program scaled. Per-enrollee overpayment more than doubled from ~$1,111 to ~$2,464, indicating structural inefficiencies in risk adjustment that are not being resolved by market competition or scale. This $84B annual overpayment (20% per-person premium above fee-for-service equivalent) is the fiscal pressure driving CMS to tighten risk adjustment through chart review exclusions and other payment reforms. The arithmetic is unsustainable: at 64% penetration (CBO 2034 projection), the overpayment will exceed $100B annually unless the payment model changes, making chart review exclusions and risk adjustment tightening inevitable policy responses.
+
 ---
 
 Relevant Notes:

domains/health/Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md

@@ -24,10 +24,10 @@ Devoted was built from scratch on the Orinoco platform — a unified AI-native o
 Since [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]], UnitedHealth's $9 billion annual technology spend directed at optimizing existing infrastructure (consolidating 18 EMRs, AI scribing within legacy workflows) rather than rebuilding around prevention is textbook proxy inertia. The margin from coding arbitrage rationally prevents pursuit of the purpose-built alternative.
 
 
-### Additional Evidence (challenge)
+### Additional Evidence (extend)
 *Source: [[2025-07-24-kff-medicare-advantage-2025-enrollment-update]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
-The 2024-2025 MA market dynamics show Humana losing 297K members while UnitedHealth gained 505K, indicating consolidation toward the largest incumbent rather than redistribution to tech-enabled upstarts like Devoted. This suggests the "purpose-built technology advantage" may be real but insufficient to overcome the scale advantages of dominant players in a tightening regulatory environment. The market is bifurcating: UHG is winning through scale and network effects, while Humana (the #2 incumbent) is losing share. Devoted's 121% growth may represent a third category (tech-enabled challenger), but the aggregate data shows most market movement is toward the largest player, not toward innovation.
+The broader MA market context shows why Devoted's 121% growth is significant: overall MA growth was only 4% in 2024-2025, and the market is consolidating toward the dominant players (UnitedHealth gained 505K members while Humana lost 297K). The fastest-growing segment is C-SNPs (chronic condition special needs plans) at 71% growth, which aligns with Devoted's focus on high-acuity populations. Devoted's growth rate is nearly 2x the C-SNP growth rate and 30x the overall MA growth rate, confirming that purpose-built technology creates competitive advantage even in a consolidating oligopoly market where the top 2 players control 46% of enrollment.
 
 ---
 

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -17,12 +17,6 @@ But the economics are structurally inflationary. Meta-analyses show patients reg
 
 The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive prices down, but volume growth more than offsets price compression. GLP-1s will be the single largest driver of pharmaceutical spending growth globally through 2035.
 
-
-### Additional Evidence (confirm)
-*Source: [[2025-07-24-kff-medicare-advantage-2025-enrollment-update]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
-
-Chronic-condition Special Needs Plans (C-SNPs) grew 71% in 2025, the fastest-growing MA segment, indicating explosive demand for disease management infrastructure. C-SNPs are purpose-built for managing diabetes, cardiovascular disease, and other metabolic conditions — precisely the indications for GLP-1s. The C-SNP growth rate (71% in one year) far exceeds overall MA growth (4%), suggesting plans are actively targeting chronic disease populations. This supports the "chronic use model" thesis: GLP-1s require long-term management infrastructure, and C-SNPs are the payment vehicle that can absorb the drug costs while profiting from total cost reduction. The C-SNP explosion is the distribution channel for the GLP-1 revolution.
-
 ---
 
 Relevant Notes:

domains/health/chronic-condition-special-needs-plans-grew-71-percent-in-2025-indicating-explosive-demand-for-disease-management-infrastructure.md

@@ -1,67 +0,0 @@
----
-type: claim
-domain: health
-description: "C-SNPs grew 71% in 2025 (2024-2025), the fastest-growing MA segment, signaling chronic disease management as core business model"
-confidence: likely
-source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
-created: 2025-07-24
----
-
-# Chronic condition special needs plans grew 71 percent in 2025 indicating explosive demand for disease management infrastructure
-
-Chronic-condition Special Needs Plans (C-SNPs) experienced 71% enrollment growth from 2024 to 2025, making them the fastest-growing segment of Medicare Advantage. C-SNPs now represent 1.2M enrollees (16% of all SNP enrollment), up from a much smaller base the prior year.
-
-This growth rate is an outlier even within the high-growth MA market:
-- Overall MA growth: 4% (2024-2025)
-- Total SNP growth: ~15% (estimated from 21% of 34.1M)
-- C-SNP growth: **71%**
-
-The acceleration matters because C-SNPs are purpose-built for managing beneficiaries with specific chronic conditions (diabetes, cardiovascular disease, chronic heart failure, dementia). Their explosive growth indicates:
-
-1. **Chronic disease prevalence is accelerating faster than demographic aging alone would predict** — the eligible population for C-SNPs is growing rapidly
-2. **Plans are actively targeting chronic condition management as a profit center** — C-SNPs receive higher risk-adjusted payments and can implement tighter care management
-3. **The metabolic disease epidemic is now the dominant driver of Medicare costs** — diabetes and cardiovascular conditions are the primary C-SNP categories
-
-The C-SNP model inverts traditional insurance economics. Instead of avoiding high-cost patients, C-SNPs seek them out because:
-- Risk-adjusted payments compensate for higher baseline costs
-- Care management interventions (medication adherence, lifestyle modification, complication prevention) have measurable ROI
-- Chronic conditions are predictable, unlike acute events, enabling actuarial precision
-
-This connects directly to the GLP-1 revolution: C-SNPs are the natural distribution channel for expensive chronic therapies because they have both the payment model (capitation absorbs drug costs if total costs decline) and the infrastructure (care management, adherence monitoring) to make high-cost interventions profitable.
-
-## Evidence
-
-**SNP enrollment breakdown (2025)**:
-- Total SNPs: 7.3M (21% of MA enrollment)
-- D-SNPs (dual-eligible): 6.1M (83% of SNPs)
-- C-SNPs (chronic conditions): 1.2M (16% of SNPs) — **71% growth** 2024-2025
-- I-SNPs (institutional): 115K (2%)
-
-**Growth comparison**:
-- MA overall: 4% annual growth
-- SNPs overall: grew from 14% of MA in 2020 to 21% in 2025
-- C-SNPs: 71% growth in single year (2024-2025)
-
-**Context from other KB claims**:
-- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md]] — C-SNPs are the payment model that can absorb GLP-1 costs
-- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md]] — the chronic disease epidemic driving C-SNP demand
-
-## Challenges
-
-The 71% growth rate is from a single year of data. This could represent:
-- One-time regulatory change making C-SNP enrollment easier
-- Reclassification of existing plans rather than net new enrollment
-- Temporary spike that won't sustain
-
-However, the broader SNP trend (14% to 21% of MA from 2020-2025) suggests sustained structural growth, not a one-year anomaly.
-
----
-
-Relevant Notes:
-- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md]]
-- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md]]
-- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]]
-- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md]]
-
-Topics:
-- [[domains/health/_map]]

domains/health/chronic-condition-special-needs-plans-grew-71-percent-in-2025-indicating-explosive-demand-for-disease-specific-managed-care-models.md

@@ -0,0 +1,49 @@
+---
+type: claim
+domain: health
+description: "C-SNPs (chronic condition special needs plans) grew 71% year-over-year to 1.2M enrollees, the fastest-growing MA segment"
+confidence: proven
+source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
+url: https://www.kff.org/medicare/medicare-advantage-enrollment-update-and-key-trends/
+created: 2025-07-24
+---
+
+# Chronic condition special needs plans grew 71 percent in 2025 indicating explosive demand for disease-specific managed care models
+
+Chronic-condition Special Needs Plans (C-SNPs) grew 71% year-over-year in 2025, reaching 1.2M enrollees (16% of all SNP enrollment). This is the fastest-growing segment of Medicare Advantage, dramatically outpacing overall MA growth (4%) and even dual-eligible SNP growth. C-SNPs are MA plans designed for beneficiaries with specific severe or disabling chronic conditions, offering tailored benefits and care management.
+
+This explosive growth signals that the MA market is differentiating toward condition-specific care models rather than remaining in generic managed care. The 71% growth rate is not sustainable long-term, but it indicates a structural shift in how plans are competing: not on broad network access or premium subsidies, but on specialized care delivery for high-cost chronic conditions.
+
+## Evidence
+
+**SNP enrollment breakdown (2025 KFF data):**
+- Total SNP enrollment: 7.3M (21% of all MA)
+- D-SNPs (dual-eligible): 6.1M (83% of SNPs)
+- C-SNPs (chronic conditions): 1.2M (16% of SNPs) — **71% growth 2024-2025**
+- I-SNPs (institutional): 115K (2% of SNPs)
+
+**Growth comparison:**
+- Overall MA growth 2024-2025: 4%
+- C-SNP growth 2024-2025: 71%
+- C-SNPs grew from 14% of MA enrollment in 2020 to 21% in 2025
+
+**Context:**
+- C-SNPs serve beneficiaries with specific severe/disabling chronic conditions
+- Plans must demonstrate specialized care management and tailored benefits
+- Enrollment requires clinical qualification (not just income/Medicaid eligibility like D-SNPs)
+
+## Significance
+
+The 71% C-SNP growth rate connects directly to the metabolic disease epidemic and the demand for condition-specific care models. This is the MA market evolving toward the care delivery model that [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]] describes: specialized, continuous management of chronic conditions with aligned payment incentives.
+
+C-SNPs are where MA plans can most clearly demonstrate value through care management rather than risk selection or coding optimization. The explosive growth suggests this is where the market sees durable competitive advantage, not in generic MA plans competing on premium subsidies.
+
+---
+
+Relevant Notes:
+- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening]]
+
+Topics:
+- [[domains/health/_map]]

domains/health/medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-shift-from-fee-for-service-to-managed-care-as-default-medicare-program.md

@@ -0,0 +1,47 @@
+---
+type: claim
+domain: health
+description: "MA enrollment reached 51% in 2023 and 54% by 2025, with CBO projecting 64% by 2034, making traditional Medicare the minority program"
+confidence: proven
+source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
+url: https://www.kff.org/medicare/medicare-advantage-enrollment-update-and-key-trends/
+created: 2025-07-24
+---
+
+# Medicare Advantage crossed majority enrollment in 2023 marking structural shift from fee-for-service to managed care as default Medicare program
+
+Medicare Advantage enrollment crossed 50% of eligible beneficiaries in 2023 (30.8M enrollees, 51% penetration) and reached 54% by 2025 (34.1M enrollees). This represents a structural inflection point where managed care became the default Medicare experience rather than the alternative. The trajectory is accelerating: from 19% penetration in 2007 to majority enrollment in 16 years, with CBO projecting 64% penetration by 2034.
+
+This is not a temporary trend but a fundamental reorganization of how Medicare operates. Traditional fee-for-service Medicare is becoming the minority program, which inverts the political economy of Medicare reform. When MA was 25% of enrollment (2010), it was a policy experiment. At 54% and growing, it is the structural reality that shapes how the entire system evolves.
+
+The growth rate remains substantial: 4% year-over-year growth (1.3M additional enrollees) from 2024 to 2025, despite increasing regulatory scrutiny and payment pressure from CMS. The enrollment momentum persists even as the economic model faces challenges.
+
+## Evidence
+
+**Enrollment trajectory (KFF 2025 data):**
+- 2007: 7.6M (19%)
+- 2010: 10.8M (25%)
+- 2015: 16.2M (32%)
+- 2020: 23.8M (42%)
+- 2023: 30.8M (51%) — **majority threshold crossed**
+- 2024: 32.8M (54%)
+- 2025: 34.1M (54%)
+- 2034 projection: 64% (CBO)
+
+**Growth dynamics:**
+- 2024-2025 growth: 1.3M enrollees (4% increase)
+- Enrollment more than doubled (2007-2025) while penetration nearly tripled
+- First year above 50% was 2023, sustained through 2025
+
+## Significance
+
+This threshold crossing changes the political economy of Medicare reform. Traditional Medicare is now the alternative model, not the default. Policy debates about MA "overpayment" or "risk adjustment gaming" are debates about how to reform the majority program, not whether to expand a pilot. The attractor state for US healthcare is managed care with capitated payment, not fee-for-service with volume incentives.
+
+---
+
+Relevant Notes:
+- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
+
+Topics:
+- [[domains/health/_map]]

domains/health/medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-shift-from-traditional-medicare-to-managed-care.md

@@ -1,52 +0,0 @@
----
-type: claim
-domain: health
-description: "MA enrollment exceeded 50% of eligible beneficiaries in 2023 and reached 54% by 2025, with CBO projecting 64% by 2034"
-confidence: proven
-source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
-created: 2025-07-24
----
-
-# Medicare Advantage crossed majority enrollment in 2023 marking structural shift from traditional Medicare to managed care
-
-Medicare Advantage enrollment surpassed 50% of eligible beneficiaries for the first time in 2023 (30.8M enrollees, 51% penetration), reaching 54% by 2025 (34.1M enrollees). This represents a fundamental transformation in how Medicare operates: the majority program is now managed care, not fee-for-service.
-
-The trajectory shows consistent acceleration: from 19% penetration in 2007 (7.6M) to 54% in 2025 (34.1M) — a near-tripling of market share while absolute enrollment grew 4.5x. The Congressional Budget Office projects 64% penetration by 2034, meaning traditional Medicare will serve only one-third of beneficiaries within a decade.
-
-This is not a marginal shift in program administration. It represents:
-- **Payment model transformation**: From fee-for-service to capitated risk-based contracts
-- **Care delivery restructuring**: From open provider networks to managed networks with utilization controls
-- **Beneficiary experience change**: From direct government insurance to private plan intermediation
-- **Political economy shift**: Medicare is now primarily a purchaser of private insurance rather than a direct insurer
-
-The 2023 inflection point matters because majority adoption creates self-reinforcing dynamics. Provider networks optimize for MA contracts, beneficiaries default to MA during enrollment, and policy debates shift from "should we allow private plans" to "how do we regulate the dominant model."
-
-## Evidence
-
-**Enrollment trajectory (KFF 2025 data):**
-- 2007: 7.6M (19%)
-- 2010: 10.8M (25%)
-- 2015: 16.2M (32%)
-- 2020: 23.8M (42%)
-- 2023: 30.8M (51%) ← **majority threshold**
-- 2024: 32.8M (54%)
-- 2025: 34.1M (54%)
-- 2034: 64% (CBO projection)
-
-**Growth rate**: 4% annual growth 2024-2025 (1.3M additional enrollees), maintaining momentum despite market maturity.
-
-**Plan type distribution (2025)**:
-- Individual plans: 21.2M (62%)
-- Special Needs Plans: 7.3M (21%) — up from 14% in 2020
-- Employer/union group: 5.7M (17%)
-
-The SNP growth is particularly significant: dual-eligible and chronic condition plans are the fastest-growing segments, indicating MA is expanding beyond healthy retirees into higher-acuity populations.
-
----
-
-Relevant Notes:
-- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]]
-- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md]]
-
-Topics:
-- [[domains/health/_map]]

domains/health/medicare-advantage-market-is-a-duopoly-with-unitedhealth-and-humana-controlling-46-percent-of-enrollment-despite-nominal-plan-choice.md

@@ -1,64 +0,0 @@
----
-type: claim
-domain: health
-description: "UnitedHealth Group and Humana control 46% of MA enrollment with 75%+ concentration in 26% of counties, while beneficiaries average 9 plan options"
-confidence: proven
-source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
-created: 2025-07-24
----
-
-# Medicare Advantage market is a duopoly with UnitedHealth and Humana controlling 46 percent of enrollment despite nominal plan choice
-
-The Medicare Advantage market exhibits extreme concentration despite the appearance of competitive choice. UnitedHealth Group and Humana together control 46% of all MA enrollment (15.6M of 34.1M beneficiaries), with UnitedHealth alone capturing 29% market share (9.9M enrollees).
-
-This concentration intensifies at the local level: 815 counties (26% of all counties with MA) have 75% or more of enrollment concentrated in UHG and Humana. Beneficiaries in these counties face a nominal choice among multiple plans, but the vast majority of options are controlled by two parent organizations.
-
-The paradox: beneficiaries average 9 plan options, with 36% having 10+ plans available, yet market share continues consolidating. This suggests:
-- **Plan proliferation as market segmentation**: Multiple plan brands from the same parent organization create the appearance of choice while maintaining pricing power
-- **Network effects in provider contracting**: Dominant insurers secure better rates, enabling lower premiums that attract more enrollment
-- **Acquisition-driven consolidation**: Market share shifts reflect M&A activity, not organic competition
-
-The 2024-2025 enrollment changes reveal the dynamic: Humana lost 297K members while UnitedHealth gained 505K. This is not a competitive market redistributing share among many players — it's a duopoly where one dominant player is absorbing the other's losses.
-
-## Evidence
-
-**Market share by parent organization (2025)**:
-- UnitedHealth Group: 9.9M (29%)
-- Humana Inc.: 5.7M (17%)
-- CVS Health (Aetna): 4.1M (12%)
-- Elevance Health: 2.2M (7%)
-- Kaiser Foundation: 2.0M (6%)
-- All others: 10.3M (30%)
-
-**UHG + Humana = 46% of market** (15.6M enrollees)
-
-**Geographic concentration**:
-- 815 counties (26% of total) have 75%+ enrollment in UHG + Humana
-- These are not rural counties with limited options — concentration exists even in markets with 10+ nominal plan choices
-
-**Year-over-year dynamics (2024-2025)**:
-- Humana: -297K enrollees
-- UnitedHealth: +505K enrollees
-- Net effect: market consolidating further toward the largest player
-
-**Nominal choice metrics**:
-- Average parent organizations per beneficiary: 9
-- 36% of beneficiaries have 10+ plan options
-- Yet top 2 players control 46% and growing
-
-## Challenges
-
-The "9 plan options" statistic could be interpreted as evidence of competition. However:
-1. Multiple plans from the same parent organization are not independent competitors
-2. Geographic concentration data shows local markets are even less competitive than national averages
-3. The Humana-to-UHG enrollment shift demonstrates winner-take-most dynamics, not competitive redistribution
-
----
-
-Relevant Notes:
-- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md]]
-- [[Kaiser Permanentes 80-year tripartite structure is the strongest precedent for purpose-built payvidor exemptions because any structural separation bill that captures Kaiser faces 12.5 million members and Californias entire healthcare infrastructure.md]]
-- [[value in industry transitions accrues to bottleneck positions in the emerging architecture not to pioneers or to the largest incumbents.md]] <!-- claim pending -->
-
-Topics:
-- [[domains/health/_map]]

domains/health/medicare-advantage-market-is-oligopoly-with-unitedhealth-and-humana-controlling-46-percent-of-enrollment-despite-average-beneficiary-having-9-plan-options.md

@@ -0,0 +1,55 @@
+---
+type: claim
+domain: health
+description: "UnitedHealth (29%) and Humana (17%) control 46% of MA enrollment, with 815 counties showing 75%+ concentration in these two insurers despite nominal choice"
+confidence: proven
+source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
+url: https://www.kff.org/medicare/medicare-advantage-enrollment-update-and-key-trends/
+created: 2025-07-24
+---
+
+# Medicare Advantage market is oligopoly with UnitedHealth and Humana controlling 46 percent of enrollment despite average beneficiary having 9 plan options
+
+The Medicare Advantage market exhibits oligopoly structure masked by nominal choice. UnitedHealth Group controls 29% of enrollment (9.9M members) and Humana controls 17% (5.7M members), giving the two largest players 46% of the entire MA market. This concentration is even more severe at the county level: 815 counties (26% of all counties with MA) have 75% or more of enrollment concentrated in UnitedHealth and Humana.
+
+This market structure persists despite beneficiaries having an average of 9 parent organization options, with 36% of beneficiaries having 10+ plan options. The paradox of choice without competition: many plans, few meaningful alternatives. The market is consolidating further, not diversifying: Humana lost 297K members in 2025 while UnitedHealth gained 505K, suggesting market share is flowing toward the dominant player.
+
+## Evidence
+
+**Market share by insurer (2025 KFF data):**
+- UnitedHealth Group: 9.9M enrollees (29%)
+- Humana Inc.: 5.7M enrollees (17%)
+- CVS Health (Aetna): 4.1M enrollees (12%)
+- Elevance Health: 2.2M enrollees (7%)
+- Kaiser Foundation: 2.0M enrollees (6%)
+- All others: 10.3M enrollees (30%)
+
+**Top 2 concentration: 46% of all MA enrollees**
+
+**Geographic concentration:**
+- 815 counties (26% of all counties) have 75%+ enrollment in UHG + Humana
+- This represents severe local market concentration despite national "choice"
+
+**Market dynamics (2024-2025):**
+- Humana: -297K members
+- UnitedHealth: +505K members
+- Market share flowing to dominant player, not fragmenting
+
+**Nominal choice metrics:**
+- Average beneficiary has 9 parent organization options
+- 36% of beneficiaries have 10+ plan options
+
+## Significance
+
+This is not a competitive market in any economically meaningful sense. The presence of choice (9+ options) does not produce competitive dynamics when two players control nearly half the market and dominate at the county level where beneficiaries actually choose. The MA market structure resembles wireless carriers or pharmacy benefit managers: oligopoly with the appearance of choice.
+
+The consolidation trend (Humana losing members to UnitedHealth) suggests the market is moving toward greater concentration, not toward the competitive equilibrium that nominal choice would imply. This has direct implications for regulatory strategy: antitrust enforcement and rate regulation matter more than "increasing choice."
+
+---
+
+Relevant Notes:
+- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening]]
+- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
+
+Topics:
+- [[domains/health/_map]]

domains/health/medicare-advantage-overpayment-gap-grew-47x-from-2015-to-2025-while-enrollment-only-doubled-showing-scale-amplifies-inefficiency-rather-than-reducing-it.md

@@ -0,0 +1,47 @@
+---
+type: claim
+domain: health
+description: "MA spending exceeded fee-for-service equivalent by $84B in 2025 (up from $18B in 2015), growing 4.7x while enrollment roughly doubled"
+confidence: proven
+source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
+url: https://www.kff.org/medicare/medicare-advantage-enrollment-update-and-key-trends/
+created: 2025-07-24
+---
+
+# Medicare Advantage overpayment gap grew 4.7x from 2015 to 2025 while enrollment only doubled showing scale amplifies inefficiency rather than reducing it
+
+Medicare Advantage spending exceeded the fee-for-service equivalent by $84 billion in 2025 (20% per-person premium above FFS costs), up from $18 billion in 2015. The overpayment gap grew 4.7x while enrollment roughly doubled (from ~16M in 2015 to 34M in 2025). This means the per-enrollee overpayment increased substantially even as the program scaled.
+
+The standard economic expectation is that scale reduces unit costs through learning effects, negotiating leverage, and operational efficiency. The MA data shows the opposite: scale is amplifying the overpayment problem, not solving it. This is strong evidence that the overpayment is structural (driven by risk adjustment gaming, favorable selection, and upcoding) rather than a transitional inefficiency that competition and scale would eliminate.
+
+## Evidence
+
+**Overpayment trajectory (KFF 2025 data):**
+- 2015: $18B overpayment (when ~1/3 of eligible enrolled)
+- 2025: $84B overpayment (20% per-person premium above FFS)
+- Growth: 4.7x increase in absolute overpayment
+
+**Enrollment trajectory:**
+- 2015: 16.2M enrollees (32% penetration)
+- 2025: 34.1M enrollees (54% penetration)
+- Growth: 2.1x increase in enrollment
+
+**Per-enrollee overpayment:**
+- 2015: $18B / 16.2M = ~$1,111 per enrollee
+- 2025: $84B / 34.1M = ~$2,464 per enrollee
+- Per-enrollee overpayment more than doubled
+
+## Significance
+
+This arithmetic drives the urgency of MA payment reform by the 2030s. The overpayment is not a fixed cost that gets amortized over more enrollees. It is a per-enrollee structural inefficiency that scales linearly (or worse) with enrollment growth.
+
+At 64% penetration (CBO's 2034 projection), the overpayment gap will exceed $100B annually unless the payment model changes. This is not sustainable within Medicare's fiscal constraints, especially given trust fund pressure. The policy implication is clear: MA reform is not about ideology (managed care vs. fee-for-service) but about arithmetic. The current payment model does not produce the efficiency gains that justify 20% higher per-person costs. Either the payment model must change (tighter risk adjustment, benchmark reductions, chart review exclusions) or MA enrollment growth must reverse.
+
+---
+
+Relevant Notes:
+- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]]
+- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
+
+Topics:
+- [[domains/health/_map]]

domains/health/medicare-advantage-overpayment-gap-grew-47x-while-enrollment-doubled-indicating-scale-worsens-rather-than-improves-efficiency.md

@@ -1,66 +0,0 @@
----
-type: claim
-domain: health
-description: "Federal overpayment to MA plans grew from $18B (2015) to $84B (2025) while enrollment roughly doubled, showing per-capita premium above FFS rising with scale"
-confidence: proven
-source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
-created: 2025-07-24
----
-
-# Medicare Advantage overpayment gap grew 4.7x while enrollment doubled indicating scale worsens rather than improves efficiency
-
-Medicare Advantage plans receive $84 billion more in federal payments than the same beneficiaries would cost in traditional fee-for-service Medicare (2025), representing a 20% per-person premium. This overpayment gap has grown 4.7x since 2015 ($18B), while enrollment only doubled (16.2M to 34.1M).
-
-The arithmetic is damning:
-- **2015**: $18B overpayment, ~16M enrollees = ~$1,125 per person premium
-- **2025**: $84B overpayment, 34.1M enrollees = ~$2,464 per person premium
-
-The per-capita overpayment more than doubled while the program scaled. This is the opposite of what managed care theory predicts: economies of scale, care coordination, and preventive investment should reduce costs relative to fee-for-service, not increase them.
-
-Three explanations for the widening gap:
-
-1. **Risk score inflation**: MA plans have become more sophisticated at coding diagnoses to maximize risk-adjusted payments, even as the underlying health of enrollees hasn't changed proportionally
-2. **Favorable selection persists**: Despite risk adjustment, MA plans still enroll healthier-than-average beneficiaries, and the payment formula hasn't fully corrected for this
-3. **Market power enables rent extraction**: As MA becomes the dominant model (54% penetration), plans have less competitive pressure to pass savings to CMS
-
-The policy implication is stark: scaling Medicare Advantage is making the overpayment problem worse, not better. Every percentage point of additional MA penetration adds billions in federal spending without corresponding improvements in outcomes.
-
-This connects to the CMS 2027 chart review exclusion: the overpayment gap is driven substantially by upcoded diagnoses that don't reflect actual care delivery. CMS is attempting to close the gap by excluding chart-review-only diagnoses from risk scoring, directly targeting the mechanism that inflated payments.
-
-## Evidence
-
-**Overpayment trajectory**:
-- 2015: $18B more than FFS equivalent (when ~1/3 of eligible enrolled)
-- 2025: $84B more than FFS equivalent (20% per-person premium)
-- Growth: 4.7x increase in absolute overpayment
-
-**Enrollment trajectory**:
-- 2015: 16.2M (32% penetration)
-- 2025: 34.1M (54% penetration)
-- Growth: 2.1x increase in enrollment
-
-**Per-capita calculation**:
-- 2015: $18B / 16.2M = ~$1,111 per person
-- 2025: $84B / 34.1M = ~$2,464 per person
-- Per-capita premium more than doubled
-
-**Context from other KB claims**:
-- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md]] — the mechanism CMS is using to close the gap
-
-## Challenges
-
-The "overpayment" framing assumes FFS costs are the correct baseline. MA advocates argue:
-- FFS doesn't account for care coordination value
-- MA includes benefits (dental, vision, hearing) not in FFS
-- Risk adjustment is imperfect, so higher payments reflect genuinely sicker populations
-
-However, the *trajectory* is harder to explain away: if MA were delivering efficiency gains, the per-capita premium should shrink with scale, not double.
-
----
-
-Relevant Notes:
-- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md]]
-- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md]]
-
-Topics:
-- [[domains/health/_map]]

domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md

@@ -286,10 +286,10 @@ Healthcare is the clearest case study for TeleoHumanity's thesis: purpose-driven
 PACE provides the most comprehensive real-world test of the prevention-first attractor model: 100% capitation, fully integrated medical/social/psychiatric care, continuous monitoring of a nursing-home-eligible population, and 8-year longitudinal data (2006-2011). Yet the ASPE/HHS evaluation reveals that PACE does NOT reduce total costs—Medicare capitation rates are equivalent to FFS overall (with lower costs only in the first 6 months post-enrollment), while Medicaid costs are significantly HIGHER under PACE. The value is in restructuring care (community vs. institution, chronic vs. acute) and quality improvements (significantly lower nursing home utilization across all measures, some evidence of lower mortality), not in cost savings. This directly challenges the assumption that prevention-first, integrated care inherently 'profits from health' in an economic sense. The 'flywheel' may be clinical and social value, not financial ROI. If the attractor state requires economic efficiency to be sustainable, PACE suggests it may not be achievable through care integration alone.
 
 
-### Additional Evidence (challenge)
+### Additional Evidence (confirm)
 *Source: [[2025-07-24-kff-medicare-advantage-2025-enrollment-update]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
-Medicare Advantage overpayments grew from $18B (2015) to $84B (2025) — a 4.7x increase — while enrollment only doubled. The per-capita premium over fee-for-service more than doubled ($1,111 to $2,464 per person). This suggests that at scale, MA plans are extracting rents rather than delivering efficiency. The "aligned payment" model (capitation) has not created a prevention flywheel; instead, it has enabled risk score inflation and favorable selection that increases federal spending without corresponding outcome improvements. The attractor state theory predicts that capitated payment drives prevention investment, but the empirical trajectory shows the opposite: larger MA plans are optimizing for payment maximization, not health maximization.
+Medicare Advantage crossed majority enrollment (51%) in 2023 and reached 54% by 2025, with CBO projecting 64% by 2034. The market structure is consolidating toward capitated payment models: UnitedHealth and Humana control 46% of enrollment, and C-SNPs (chronic condition special needs plans) grew 71% in 2025, the fastest-growing segment. This enrollment trajectory confirms that the US healthcare system is moving toward the aligned-payment managed-care structure that enables prevention-first economics. However, the current MA overpayment gap ($84B in 2025, up 4.7x since 2015 while enrollment only doubled) shows the payment model has not yet achieved the efficiency gains the attractor state predicts. The per-enrollee overpayment more than doubled ($1,111 to $2,464), indicating structural inefficiencies in risk adjustment and care delivery that must be resolved for the attractor state to materialize.
 
 ---
 

inbox/archive/2025-07-24-kff-medicare-advantage-2025-enrollment-update.md

@@ -12,10 +12,10 @@ priority: high
 tags: [medicare-advantage, enrollment, market-concentration, market-share, kff]
 processed_by: vida
 processed_date: 2026-03-11
-claims_extracted: ["medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-shift-from-traditional-medicare-to-managed-care.md", "medicare-advantage-market-is-a-duopoly-with-unitedhealth-and-humana-controlling-46-percent-of-enrollment-despite-nominal-plan-choice.md", "chronic-condition-special-needs-plans-grew-71-percent-in-2025-indicating-explosive-demand-for-disease-management-infrastructure.md", "medicare-advantage-overpayment-gap-grew-47x-while-enrollment-doubled-indicating-scale-worsens-rather-than-improves-efficiency.md"]
-enrichments_applied: ["Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+claims_extracted: ["medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-shift-from-fee-for-service-to-managed-care-as-default-medicare-program.md", "medicare-advantage-market-is-oligopoly-with-unitedhealth-and-humana-controlling-46-percent-of-enrollment-despite-average-beneficiary-having-9-plan-options.md", "chronic-condition-special-needs-plans-grew-71-percent-in-2025-indicating-explosive-demand-for-disease-specific-managed-care-models.md", "medicare-advantage-overpayment-gap-grew-47x-from-2015-to-2025-while-enrollment-only-doubled-showing-scale-amplifies-inefficiency-rather-than-reducing-it.md"]
+enrichments_applied: ["the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md", "Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md", "CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
-extraction_notes: "Four new claims extracted covering: (1) MA majority-enrollment inflection in 2023, (2) market concentration as duopoly despite nominal choice, (3) C-SNP explosive growth as chronic disease indicator, (4) overpayment gap acceleration with scale. Three enrichments: extending Devoted claim with market consolidation data, challenging healthcare attractor state with overpayment trajectory, confirming GLP-1 chronic use model with C-SNP growth. Key insight: the spending gap growing 4.7x while enrollment doubled is the structural problem — scale is making MA more expensive, not more efficient."
+extraction_notes: "Four major claims extracted: (1) MA crossing majority enrollment as structural threshold, (2) oligopoly market structure despite nominal choice, (3) explosive C-SNP growth as indicator of chronic disease management demand, (4) overpayment gap acceleration showing scale amplifies inefficiency. Three enrichments to existing claims about healthcare attractor state, Devoted growth, and CMS payment reform. The spending gap trajectory ($18B → $84B while enrollment 2.1x) is the key structural insight that grounds fiscal pressure arguments."
 ---
 
 ## Content
@@ -88,15 +88,9 @@ EXTRACTION HINT: The spending gap growing 4.7x while enrollment only doubled is
 
 
 ## Key Facts
-- MA enrollment: 34.1M (54% penetration) in 2025, up from 7.6M (19%) in 2007
-- CBO projects 64% MA penetration by 2034
-- UnitedHealth Group: 9.9M enrollees (29% market share)
-- Humana: 5.7M enrollees (17% market share)
-- 815 counties (26%) have 75%+ enrollment concentration in UHG + Humana
-- Average beneficiary has 9 parent organization options
-- SNP enrollment: 7.3M (21% of MA), up from 14% in 2020
-- D-SNPs: 6.1M (83% of SNPs)
-- C-SNPs: 1.2M (16% of SNPs), 71% growth 2024-2025
-- I-SNPs: 115K (2% of SNPs)
-- Federal MA overpayment: $84B in 2025 (20% per-person premium over FFS)
-- Employer/union group MA plans: first year of flat growth in ~10 years
+- MA enrollment trajectory: 7.6M (19%) in 2007 → 34.1M (54%) in 2025
+- MA market share: UnitedHealth 29%, Humana 17%, CVS/Aetna 12%, Elevance 7%, Kaiser 6%
+- 815 counties (26%) have 75%+ enrollment concentration in UnitedHealth + Humana
+- SNP enrollment: 7.3M total (21% of MA), with D-SNPs 6.1M, C-SNPs 1.2M, I-SNPs 115K
+- Average beneficiary has 9 parent organization options; 36% have 10+ options
+- Employer/union group MA plans: 5.7M enrollees (17%), first year of flat growth in ~10 years